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Abstract
Following the current epidemic of obesity, the worldwide 
prevalence of nonalcoholic fatty liver disease (NAFLD) 
has increased with potential serious health implications. 
While it is established that in adults NAFLD can 
progress to end-stage liver disease in many cases, the 
risk of progression during childhood is less well defined. 
Since most obese children are not adherent to lifestyle 
modifications and hypocaloric diets, there is a growing 
number of studies on pharmacological interventions 
with the risk of disease mongering, the practice of 
widening the boundaries of illness in order to expand 
the markets for treatment. Here, we propose a critical 
appraisal of the best available evidence about long-term 
course of pediatric NAFLD and efficacy of treatments 
other than hypocaloric diet and physical exercise. As 
a result, the number of NAFLD children with a poor 
outcome is small in spite of the alarming tones used in 
some papers; large-scale longitudinal studies with long-
term follow-up of pediatric NAFLD patients are lacking; 
the studies on ancillary pharmacological interventions 
have been performed in few patients with inconclusive 
and conflicting results. 
Key words: Obesity; Children; Non alcoholic fatty liver 
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Core tip: The number of obese children with nonal-
coholic fatty liver with a documented poor outcome 
is small in spite of the alarming tones used in some 
papers. The available studies are insufficient to 
determine whether or not children with nonalcoholic 
fatty liver have an elevated risk of developing 
detrimental health conditions. Large-scale longitudinal 
studies with long-term follow-up of children with 
nonalcoholic fatty liver are desirable. Since most obese 
children are not adherent to lifestyle modifications 
and hypocaloric diets, there is a growing number of 
studies on pharmacological interventions with the risk 
of disease mongering, the practice of widening the 
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boundaries of illness in order to expand the markets 
for treatment. The studies on ancillary pharmacological 
interventions, in addition to diet and exercise, have 
been performed in few children with inconclusive and 
conflicting results. The proposal to the obese patient of 
an ancillary drug may divert his attention from the diet 
and exercise. 
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INTRODUCTION
Childhood obesity can adversely affect nearly every 
organ system with increased mortality in adult life from 
a wide variety of systemic diseases[1]. Following the 
current epidemic of obesity, the worldwide prevalence 
of nonalcoholic fatty liver disease (NAFLD) has doubled 
during the last 20 years with consequent potential 
serious health implications[2].
In adults NAFLD has been reported to progress to 
fibrosis and end-stage liver disease in some 15%-20% 
of cases, sometimes with need of liver transplan-
tation[1,3]. Data on fibrosis, evolution to cirrhosis and/or 
liver cancer in large cohorts of children with NAFLD 
followed up long-term are scarce[1]. Despite this lack 
of information, there is a widespread tendency to 
draw alarming scenarios also for childhood NAFLD[4-6], 
bordering on the phenomenon of so called “disease 
mongering”, i.e. the practice of widening the diagnostic 
boundaries of illnesses and aggressively promoting 
their public awareness in order to expand the markets 
for treatment[7-9]. This concept is strictly related to 
medicalization, which implies an extension of medicine 
domain on three possible ways: qualitative (disease 
or not disease), quantitative (lowering threshold), 
temporal (antedating a diagnosis)[7-9]. It has been 
reported that the phenomenon of disease mongering 
is supported by informal alliances comprising drug 
company staff, physicians and consumer groups, which 
tend to promote a view of their particular condition 
as widespread, serious, and treatable[8]. In many 
cases these alliances are not maliciously preconceived 
and simply reflect the fear towards some conditions 
deemed dangerous to health[10]. Given the severe well-
documented impact of obesity on health, for which it 
has been stated that we may see the first generation 
that will be less healthy and have a shorter life 
expectancy than their parents[11], it seems paradoxical 
to invoke the phenomenon of “disease mongering” for 
obesity-related liver disease. Nevertheless, in the case 
of obesity there are many myths and presumptions not 
scientifically supported[12]. Therefore, we think that the 
impact of pediatric NAFLD on morbidity and mortality 
must be critically evaluated.
Risk of progression of pediatric NAFLD toward end-
stage liver disease
As recently reported[1], there is only one long-term 
outcome study on the natural history of NAFLD in 
children, which emphasizes the risk of an unfavorable 
evolution[4]. In this paper 66 children with NAFLD were 
enrolled and only 29 patients underwent a baseline 
liver biopsy, 5 of whom also had a follow-up histology. 
Moreover, a substantial proportion of the patients 
enrolled in this study, considered the reference paper 
for the natural history of children with obesity-related 
liver disease[1], were not obese (34%) and did not 
have metabolic syndrome (17%). Anyway, only two 
patients required liver transplantation: an 11-year-old 
Hispanic female, with a body mass index (BMI) of 26.9 
kg/m2, dyslipidemia, cirrhosis and esophageal varices 
at onset, transplanted at the age of 20 years for 
hepatopulmonary syndrome, with recurrence of NAFLD 
after 9 mo; and a 18.9-year-old female with a BMI 
of 33.6 kg/m2, low HDL level and hepatopulmonary 
syndrome, transplanted at the age of 25 years, re-
transplanted for recurrence of NAFLD 2.3 years after, 
who died from multiple organ failure at the age of 27 
years. 
Both cases had a very severe and atypical clinical 
course with early recurrence of NAFLD after liver 
transplantation, suggesting that they might have 
been affected by an unrecognized genetic metabolic 
disorder other than NAFLD. In this respect, very 
little information is provided in the paper on what 
investigations were done to exclude underlying chronic 
liver disease. It is to note that hypothalamic-pituitary 
axis dysfunction and lysosomal acid lipase deficiency (in 
which the recurrence of non alcoholic steatohepatitis 
(NASH) following liver transplantation is common) 
were not ruled out[13].
In Feldstein’s study there were only two children 
with cirrhosis and these were the same two who 
required liver transplantation[4]. Overall, four children 
were included in the poor prognosis group: the two 
transplanted and two who died for complications 
related to bariatric surgery and whose death was not 
liver related. On the basis of the outcome of these 
four “atypical” patients with NAFLD, a standardized 
mortality risk of 13.6 was assigned to the category of 
the children with NAFLD in comparison with general 
population.
In the introduction of Feldstein’s report[4], particular 
emphasis is attributed to some cases of cirrhotic stage 
disease in children with NAFLD previously reported 
in literature. If we analyze the relative references, 
we realize that overall a total of only 5 cases were 
reported. These 5 cases included a 12-year-old boy 
with craniopharyngioma with secondary obesity[14], 
and a patient who developed at the age of 30 years 
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hypertransaminasemia without evidence of metabolic 
syndrome with hepatic decompensation at 32 
years[15]. Interestingly, though this patient had a low 
ceruloplasmin, Wilson disease was excluded only on 
the basis of urinary copper excretion[15]. The other 
two patients were drawn out of two case studies: 
one reported in 2003 by Schwimmer including 43 
obese children[16] and the other reported in 1984 
including 299 patients[17]. In these two studies further 
details about the two patients with cirrhosis were not 
provided. 
Therefore, the critical analysis of the study[4] and its 
references shows that progressive liver disease is not 
a common complication of pediatric NAFLD[14-17]. 
Among the other reports of cirrhosis in children with 
NAFLD not cited in Feldstein’s study[4], one showed 
3 cases of cirrhosis and 8 cases of advanced fibrosis 
among 100 children with histologically documented 
NAFLD[18]. Unfortunately, further details about these 
patients with severe histology were not provided 
also in this study which, however, documented fi-
brosis absent or mild in about two thirds of cases[18]. 
Furthermore, an Italian study evaluating liver histology 
on a large sample of 203 children with NAFLD showed 
no case of stage 4 fibrosis and/or cirrhosis[19]. 
So far, the histologic evolution of children with 
NAFLD has been evaluated in few longitudinal 
studies[20,21]. In a cohort of one-hundred six children, 7 
cases (6.6%) had a stage 3-4 fibrosis[21]. Paradoxically, 
these patients were significantly younger compared 
with those with mild or no fibrosis. Although the 
enrolled patients had an accurate histological eval-
uation, only 46 patients (43%) were investigated for 
metabolic syndrome[21]. 
At the present time, severe cases seem to be too 
few to refute the arguments on the generally favorable 
course of pediatric NAFLD as supported from the 
literature analysis performed here and elsewhere[1]. 
Table 1[4,14-19,21-24] summarizes pediatric studies on 
NAFLD with indication of the cases of end stage-liver 
disease. Unfortunately, none of them provided long 
enough follow-up to assess long-term cumulative risk 
of severe outcomes. It is to note that almost all the 
evaluations  were assessed in individuals under 20 
years of age. 
Risk of liver transplant for pediatric NAFLD
While NASH has become the second leading etiology of 
liver disease among adults awaiting liver transplantation, 
little information is available for children[1]. A recent 
paper from the States reports that NASH may be an 
important cause of transplant also in children and young 
adults[5]. The study included United States patients 
under 40 years of age transplanted for NASH (no 
information about the etiology of NASH was provided 
in the paper) and for cryptogenic cirrhosis associated 
with a BMI > 30 kg/m2. The overall frequency of 
transplantation for NASH and cryptogenic cirrhosis 
associated with obesity was only 1.67% (330/19904), 
though this low percentage was not emphasized in the 
conclusions. Of interest, among these patients only 4.2% 
were < 18 years old, while 16.4% were between 18 
and 29 years and 79.4 % between 30 and 40 years of 
age, suggesting that NAFLD is not a frequent indication 
for transplantation in children. Moreover, some 15% of 
the patients had a BMI < 25 kg/m2 and therefore were 
not obese.
Despite this, the study is frequently cited to 
stress the high risk for liver transplantation in obese 
children[1]. To reinforce the concept that fatty liver due 
to obesity is rarely leading to liver transplantation is 
the observation that no children with NAFLD required 
liver transplant in large pediatric series in Europe and 
United States[25-28].
Risk of hepatocellular carcinoma among children with 
NAFLD
Though it has been frequently stated that NAFLD 
can progress to hepatocellular carcinoma in children, 
because of the role of obesity and insulin resistance 
in carcinogenesis, Nobili et al[1] reported that “only 
two cases have been described to date, in both cirrho-
tic and non-cirrhotic background”. Is it reasonable 
to conclude that these cases of HCC are causally 
associated with obesity? Or, more likely, was it just a 
fortuity? In brief, given the paucity of data showing a 
direct correlation between the progression of NAFLD 
and hepatocellular carcinoma, currently, the risk 
estimates are not clear and NAFLD can be considered 
a risk factor likely but not certain. However, what is 
proved by the evidence is that childhood obesity by 
itself increases the risk of liver cancer in adulthood, 
as well as other carcinomas[12,29]. Therefore it appears 
more important to focus on the systemic impact of 
obesity in general rather than on the fatty liver.
Treatment of NAFLD in children
All studies accept the premise that the most effective 
treatment for patients with NAFLD, both adults 
and children, is lifestyle optimization, with a focus 
on nutrition and exercise. These measures have 
been proven to be able to revert liver damage[1]. 
Unfortunately, the majority of obese children are not 
adherent to lifestyle modifications and hypocaloric 
diets[30]. Therefore, there is a growing number of 
studies focused on pharmacological interventions, 
based on proven or perceived mechanisms involved in 
the pathogenesis of NAFLD. In children, most of these 
studies have been generally performed in small series 
of patients with conflicting and sometimes inconclusive 
results[31,32]. The evaluation of the effectiveness of 
the various drugs is based in most cases on serum 
levels of transaminases with few determinations after 
a short-term intervention[31,32]. Long-term results of 
these treatments and their ability to modify the natural 
course of NAFLD are not available.
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vitamin E on ballooning degeneration, documented in 
TONIC trial, one of the best designed pediatric studies 
in a large sample of NAFLD patients[40]. This finding, 
although the Authors clearly stated that neither vitamin 
E nor metformin were superior to a placebo in attaining 
sustained reduction in ALT level (primary outcome) 
or improvement in fibrosis (secondary outcome) in 
patients with pediatric NAFLD, can encourage the use 
of vitamin E in patients with NAFLD. As stated before, 
it is important to understand if a therapeutic agent has 
an impact on a single parameter (liver enzymes) in 
a limited time interval or an impact on the long term 
course of disease. If we accept the hypothesis that a 
treatment with probiotics can really have a favorable 
impact on liver injury, as a result, probiotics should 
be prescribed, on a regular basis, to the patient in 
addition to the recommendation of reducing caloric 
intake and increasing physical activity. Given the long 
life expectancy of pediatric patients and the need of 
preserving obesity-related liver damage in the long 
term, for how many years (decades?) probiotics should 
be prescribed in addition to lifestyle modification? 
and with what economic cost? Furthermore, we must 
consider that the proposal to the obese patient of an 
ancillary drug, in addition to diet and exercise, may 
divert his attention from the diet and exercise.
Despite the absence of strong evidence and 
although the majority of the Authors is cautious in 
recommending the extensive use of these drugs[1], it 
is reasonable to fear a strong demand from parents 
who see the drug as a potential remedy for the 
liver disease of their child. Furthermore, it creates a 
favorable environment for the development of the 
phenomenon of disease mongering. Of course, with 
these considerations we do not deny the usefulness 
of research on the potential role of drugs and food 
Since many studies in humans have shown a 
relationship between gut bacterial overgrowth, enhanced 
gut permeability, increased paracellular leakage of gut 
luminal antigens and liver disease progression through 
an increased exposure of the liver to gut-derived bacterial 
products[33,34], modulating gut microbiota with probiotics, 
prebiotics, and synbiotics has become an attractive, safe 
and well tolerated treatment strategy of obesity and 
NAFLD. Nevetheless, also in adults, their therapeutic 
use is not supported by high-quality clinical studies[34,35]. 
Unfortunately, the only two pediatric RCTs, evaluating 
the influence of either single strain (Lactobacillus 
rhamnosus strain GG)[36] or multistrain VSL#3[37] 
probiotic supplementation on hepatic biomarkers in 
small groups of patients (20 and 40, respectively), 
gave different results. Vajro et al[36] reported no effect 
of L. rhamnosus strain GG on liver echogenicity, but 
a decrease in serum alanine aminotransferase levels 
in children treated with L. rhamnosus strain GG as 
compared to placebo. Conversely, Alisi et al[37] found 
that VSL#3 supplementation reduced the severity of 
steatosis as assessed by ultrasound. These findings were 
observed in short periods (2 and 4 mo, respectively) 
and with a single evaluation at the end of the study. 
From a pathophysiological point of view, it is difficult 
to understand how a short term intervention, as 
administration of probiotic for few months, could have 
such a long term impact on the composition of the 
intestinal microbiota (which is highly mutable and related 
to prenatal, perinatal and environmental factors)[38,39] 
to the point of affecting liver health. In particular, the 
problem is to hypothesize a lasting effect over time, 
given that the complications of NAFLD are expected in 
the long term. 
Another critical point is the risk of stressing the 
beneficial effect of a drug on a limited aspect, albeit 
important, of a disease. This could be the case of 
Table 1  Studies with histologically documented cases of advanced liver disease in pediatric nonalcoholic fatty liver disease
Study Yr No. of patients Age (yr) Follow-up (yr) Case of cirrhosis Progression of 
fibrosis (n)
Case of liver 
transplantation (n)(n)
Cross-sectional studies
Kinugasa et al[17] 1984 299 N/A N/A 1 N/A N/A
Schwimmer et al[16] 2003   43 N/A N/A 1 N/A N/A
Suzuki et al[15] 2005     1 12 N/A 1 N/A N/A
Schwimmer et al[18] 2005 100 Range 2-18 N/A 3 N/A N/A
Alkhouri et al[19] 2012 203 Mean 12.4 N/A 0 N/A N/A
Longitudinal studies
Molleston et al[14] 2002     2 10 and 14 N/A 2 2/2 None
Feldstein et al[4] 2009   66 Mean 13.9 6.4 2 4/5 2
(5 followed 
longitudinally)
A-Kader et al[21] 2008 106 Range 7-19 2.3 2 7/18 N/A
(18 followed 
longitudinally)
Lavine et al[22] 2012 (preliminary report)   58 Range 8-17 1.8 N/A 15/58 N/A
Brunt et al[23] 2014 (preliminary report) 102 Range 11-17 2.2 N/A 20/102 N/A
Alkhouri et al[24] 2015 (preliminary report) 330 4-40 N/A N/A N/A 14/330 
N/A: Not available.
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supplements in the therapy of this condition. What we 
hope however is that their effectiveness is documented 
with a robust methodology and on large series, that 
are actually missing. 
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